Rapid and sustained improvements in itch and sleep with tralokinumab treatment in patients with moderate-to-severe Atopic Dermatitis, a post hoc analysis of pooled data from ECZTRA 1 and 2

Main Article Content

Eric Simpson
Oregon Medical Research Center, Portland, OR, USA

Anderas Wollenberg
Department of Dermatology and Allergy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany

Weily Soong
Alabama Allergy & Asthma Center and Clinical Research Center of Alabama, Birmingham, AL, United States

Thomas Mark
LEO Pharma A/S, Ballerup, Denmark

Alexandra Kuznetsova
LEO Pharma A/S, Ballerup, Denmark

Louise Abildgaard Steffensen
LEO Pharma A/S, Ballerup, Denmark

Jonathan Silverberg
George Washington University School of Medicine

Keywords

tralokinumab, atopic dermatitis, itch, sleep

Abstract

N/A

References

1. Wollenberg A et al. Br J Dermatol. 2020 Sep 30. doi: 10.1111/bjd.19574. Online ahead of print

Article Sidebar

Poster PDF
Published
Nov 5, 2021
DOI https://doi.org/10.25251/skin.5.supp.61

Article Details

How to Cite
Simpson, E., Wollenberg, A., Soong, W., Mark, T., Kuznetsova, A., Abildgaard Steffensen, L., & Silverberg, J. (2021). Rapid and sustained improvements in itch and sleep with tralokinumab treatment in patients with moderate-to-severe Atopic Dermatitis, a post hoc analysis of pooled data from ECZTRA 1 and 2. SKIN The Journal of Cutaneous Medicine, 5(6), s61. https://doi.org/10.25251/skin.5.supp.61
Issue
Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 > >>